rna
interfer
rnai
mechan
silenc
gene
express
conserv
evolut
eukaryot
rang
plant
process
cellular
complex
dicer
cleav
doublestrand
rna
dsrna
molecul
yield
doublestrand
duplex
nucleotid
length
short
interf
rna
sirna
guid
rnaiinduc
silenc
complex
risc
cleav
target
mrna
share
sequenc
ident
sinc
first
demonstr
ad
exogen
synthet
sirna
molecul
mammalian
cell
induc
rapidli
expand
effort
develop
rnai
therapi
induc
degrad
target
messeng
rna
mrna
involv
genet
inherit
ie
domin
acquir
disord
review
focu
featur
challeng
uniqu
appli
rnai
toward
one
import
class
acquir
diseas
viral
infect
rnai
well
suit
antivir
therapi
numer
reason
antivir
therapeut
hing
upon
abil
discrimin
viru
host
howev
virus
reli
extens
upon
host
cell
mani
function
activ
involv
viral
replic
therefor
typic
offer
limit
number
therapeut
target
exampl
major
antihiv
small
molecul
drug
use
highli
activ
antiretrovir
therapi
haart
focu
one
two
viral
enzym
revers
transcriptas
contrast
rnai
target
short
stretch
viral
nucleic
acid
rather
function
domain
viral
protein
even
small
viral
genom
offer
larg
number
potenti
target
furthermor
principl
develop
rnai
therapeut
begin
viral
genom
sequenc
known
wherea
develop
small
molecul
therapi
inhibit
complex
protein
activ
requir
prior
elucid
much
biolog
function
detail
final
although
limit
evid
rnai
play
natur
antivir
role
mammalian
clear
serv
import
defens
virus
plant
transpos
element
caenorhabd
therefor
human
virus
may
prove
particularli
fruit
therapeut
target
evolutionarili
conserv
mechan
along
potenti
advantag
featur
virus
pose
number
uniqu
challeng
rnaibas
therapi
virus
replic
extrem
rapidli
accumul
mutat
short
delet
particularli
virus
life
cycl
involv
rna
genom
discuss
detail
sinc
rnai
reli
upon
nearli
perfect
sequenc
ident
sirna
guid
mrna
target
accumul
mutat
render
viru
resist
rnai
suppress
analog
evolut
viral
resist
furthermor
viral
replic
dsrna
encod
viral
protein
full
genom
often
gener
potenti
expos
viru
host
cell
rnai
result
surpris
numer
virus
evolv
effici
suppressor
rnai
although
phenomenon
better
character
plant
infect
anim
appar
presenc
rnai
suppressor
human
virus
indic
could
impact
antivir
rnai
instanc
vaccinia
influenza
protein
suppress
rnai
express
heterolog
although
yet
clear
whether
activ
intent
evolv
viru
side
effect
abil
protein
bind
dsrna
furthermor
recent
report
human
immunodefici
viru
type
transcript
activ
protein
tat
also
suppress
rnai
directli
inhibit
target
earli
stage
viral
life
cycl
suppressor
accumul
directli
target
suppressor
mrna
may
necessari
circumv
mechan
viral
resist
gener
rnaiinduc
cargo
deliveri
system
design
match
life
cycl
patholog
target
viru
first
option
deliv
synthet
sirna
molecul
either
nake
complex
synthet
altern
one
deliv
plasmid
viral
vector
construct
induc
cell
transcrib
two
complementari
rna
molecul
hybrid
gener
sirna
short
hairpin
rna
shrna
fold
yield
dicer
synthet
sirna
provid
rapid
transient
suppress
appropri
acut
viral
infect
influenza
wherea
deliveri
express
construct
provid
sustain
rnai
suitabl
chronic
infecti
hepat
likewis
deliveri
focus
tissu
target
pathogen
resid
replic
somewhat
analog
target
vaccin
deliveri
focu
immun
tissu
lie
pathogen
infecti
rout
entri
exampl
influenza
respiratori
syncyti
viru
rsv
therapi
appropri
deliv
wherea
hepat
therapi
administ
intraven
liver
similarli
cell
macrophag
protect
hiv
harvest
transduc
hematopoiet
stem
cell
viru
ex
vivo
introduc
antihiv
rnai
addit
rnaiinduc
nucleic
acid
must
deliv
within
therapeut
window
dosag
dosedepend
observ
vitro
vivo
lentivir
vector
deliveri
shrnaexpress
construct
progress
knock
target
gene
express
singl
cell
increas
viral
likewis
studi
intranas
deliveri
polyplex
deliveri
vehicl
compos
synthet
antiinfluenza
sirna
polycation
polym
polyethylenimin
higher
sirna
dose
protect
mice
challeng
influenza
effici
nucleic
acid
deliveri
major
challeng
parallel
field
gene
therapi
deliveri
vehicl
rout
administr
rnaiinduc
cargo
benefit
prior
continu
progress
synthet
viral
vector
addit
lower
deliveri
limit
efficaci
sever
phenomena
restrict
maxim
dosag
rnai
host
toler
long
dsrna
natur
substrat
dicer
process
gener
sirna
known
activ
protein
kinas
r
therebi
induc
interferon
express
wherea
sirna
typic
associ
innat
immun
respons
howev
high
dosag
synthet
sirna
deliveri
stimul
cytotox
interferon
inflammatori
cytokin
secret
sequencedepend
addit
sirna
target
degrad
mrna
high
degre
sequenc
specif
case
also
elimin
mrna
contain
similar
sequenc
lead
broader
unintend
modul
host
gene
nonspecif
offtarget
effect
lead
possibl
clinic
side
effect
furthermor
shrna
interact
anoth
endogen
cellular
pathway
suppress
gene
express
microrna
mirna
system
mirna
initi
transcrib
partial
doublestrand
precursor
subsequ
process
rnase
iii
enzym
drosha
yield
rna
hairpin
hairpin
export
nucleu
exportin
subsequ
suppress
cytoplasm
translat
target
mrna
exogen
shrna
express
nucleu
therapeut
gene
deliveri
also
undergo
exportin
nuclear
export
satur
transport
recent
report
demonstr
higheffici
deliveri
certain
antihepat
shrna
express
construct
murin
liver
use
vector
base
adenoassoci
viru
serotyp
could
induc
signific
liver
toxic
like
competit
inhibit
endogen
mirna
final
rnai
pathway
consum
signific
amount
atp
constitut
express
sirna
shrna
construct
could
metabol
tax
host
one
approach
overcom
side
effect
limit
rnai
cell
infect
viral
pathogen
creation
shrna
express
construct
driven
rna
polymeras
ii
promot
enabl
develop
regul
promot
activ
viral
infect
exampl
recent
studi
antihepat
c
viru
hcv
sirna
construct
insert
front
hiv
ltr
promot
contain
two
respons
element
therebi
activ
hcv
infect
deliveri
construct
cell
transfect
fulllength
hepat
c
viru
cdna
significantli
silenc
viral
gene
similarli
unwalla
et
describ
tatinduc
vector
condit
express
antihiv
shrna
hiv
present
therebi
inhibit
hiv
via
neg
feedback
mechan
altern
synthet
sirna
administ
upon
viral
infect
develop
target
deliveri
system
may
enabl
specif
deliveri
affect
cell
despit
challeng
larg
grow
bodi
work
demonstr
farreach
promis
antivir
rnai
obstacl
fulli
overcom
rnai
use
inhibit
express
block
replic
broad
rang
viral
speci
mani
famili
human
mammalian
pathogen
summar
tabl
howev
virus
vari
wide
basic
biolog
reproduct
mechan
suggest
uniqu
strategi
need
inhibit
particular
viru
see
figur
rnai
current
understood
riscmedi
rna
cleavag
restrict
cytoplasm
locat
target
molecul
sinc
virus
hijack
cellular
translat
machineri
express
protein
target
viral
encod
cytoplasm
mrna
common
locu
virus
suscept
inhibit
support
assert
shown
broad
spectrum
virus
inhibit
target
essenti
viral
mrna
date
list
virus
success
inhibit
manner
includ
viru
ebv
footandmouth
diseas
viru
fmdv
hepat
b
viru
hbv
hepat
c
viru
hcv
human
immunodefici
viru
type
human
papilloma
viru
hpv
influenza
viru
iva
marburg
human
parainfluenza
viru
piv
sever
acut
respiratori
syndrom
associ
coronaviru
sarscov
vesicular
stomat
viru
vsv
west
nile
viru
wnv
case
inhibit
achiev
directli
reduc
virus
abil
reproduc
howev
butz
et
demonstr
hpv
pathogenesi
could
reduc
target
viral
inhibitor
apoptosi
limit
viral
spread
select
induc
apoptosi
hpvinfect
cell
exampl
also
illustr
type
viral
infect
offer
uniqu
treatment
option
tailor
rnaibas
therapi
particular
viru
import
consider
uniqu
life
cycl
viru
first
degre
approxim
life
cycl
group
type
nucleic
acid
viral
genom
compos
virus
dna
genom
sole
option
target
viral
mrna
exampl
target
hpv
mrna
suffici
block
viral
replic
reduc
howev
target
virus
positivestrand
rna
genom
viral
genom
transcrib
orient
viral
mrna
genom
rna
mrna
might
degrad
simultan
due
fact
share
sequenc
ident
direct
cleavag
positivestrand
genom
rna
demonstr
hbv
pregenom
rna
serv
mrna
templat
revers
transcript
genom
dna
appear
similarli
yet
clear
whether
simultan
degrad
genom
mrna
underli
observ
viral
inhibit
positivestrand
rna
virus
situat
appear
complex
target
virus
negativestrand
rna
genom
exampl
shown
appli
antiinfluenza
viru
sirna
could
potenti
induc
rnai
either
sens
rna
mrna
genomecomplementari
rna
made
replic
antisens
rna
genom
rna
mrna
suscept
riscmedi
select
potenti
due
partial
fact
influenza
viral
replic
take
place
nucleu
isol
protect
viral
rna
risc
howev
similar
differenti
suscept
viral
mrna
genom
rna
also
observ
target
rsv
negativestrand
rna
rotaviru
dsrna
latter
virus
reproduc
cytoplasm
thu
suscept
risc
howev
viral
mrna
degrad
select
vulner
least
partli
explain
fact
genom
rna
cytoplasm
replic
virus
tightli
bound
viral
protein
may
protect
rna
risc
moreov
sinc
effect
sirna
load
asymmetr
risc
prefer
one
strand
unlik
negativestrand
rna
genom
viral
mrna
target
simultan
singl
howev
synergist
efficaci
could
obtain
target
rnabind
protein
express
cytoplasm
replic
rna
virus
sinc
inhibit
could
repress
product
new
virus
render
genom
rna
suscept
rnaimedi
cleavag
case
clear
uniqu
viral
replic
mechan
must
taken
consider
achiev
maxim
rnaimedi
inhibit
one
drawback
target
viral
gene
rnai
viral
mutat
lead
loss
sensit
rnai
especi
problemat
possibl
case
rna
virus
accumul
point
mutat
rapidli
counterpart
dna
illustr
problem
rnairesist
mutant
aros
cell
cultur
model
target
although
mutant
achiev
resist
point
mutat
delet
target
sequenc
one
hiv
mutant
escap
rnai
suppress
accumul
mutat
outsid
target
sequenc
therebi
creat
new
local
rna
secondari
structur
presum
exclud
result
demonstr
conclus
effect
rnaibas
antivir
therapi
must
compens
evolutionari
potenti
pathogen
possibl
problem
viral
evolut
circumv
direct
rnai
essenti
cellular
cofactor
ideal
loss
cellular
target
must
block
viral
replic
without
induc
loss
function
patholog
cell
exampl
hiv
util
chemokin
receptor
coreceptor
cell
entri
downregul
gene
immun
cell
rnai
block
hiv
importantli
human
homozyg
delet
abolish
express
appar
normal
immun
function
natur
resist
addit
target
cellular
receptor
could
truli
protect
cell
initi
viral
infect
rather
impair
postinfect
viral
reproduct
target
viral
gene
achiev
addit
produc
block
viral
entri
step
could
strand
viru
extracellular
space
greater
amount
time
render
suscept
immun
surveil
clearanc
final
viru
compens
loss
primari
receptor
andor
coreceptor
would
need
make
challeng
evolutionari
leap
compar
acquir
novel
tissu
tropism
cross
speci
barrier
addit
cell
surfac
receptor
number
host
cellular
rnai
target
provid
block
intracellular
step
also
identifi
exampl
complex
mediat
nucleat
step
actin
polymer
mechan
use
virus
bacteria
intracellular
transport
hiv
infect
accordingli
halt
step
intracellular
traffick
nucleu
cellular
downregul
poli
adpribos
polymeras
abolish
hiv
integr
interf
activ
gene
includ
hiv
long
termin
repeat
ltr
also
possibl
imped
viral
regulatori
function
target
cellular
protein
interact
viral
regulatori
factor
initi
viral
transcript
exampl
hiv
gene
express
replic
critic
depend
upon
recruit
host
transcript
complex
ptefb
compos
cyclin
viral
protein
tat
rnai
target
cyclin
shown
impair
hiv
addit
sever
attenu
viral
replic
observ
rnai
direct
either
human
revinteract
protein
hrip
requir
hiv
revmedi
nuclear
export
unsplic
viral
genom
analog
work
hiv
htlv
taxmedi
transcript
activ
block
target
essenti
cellular
factor
recruit
viral
furthermor
hcv
replic
reduc
direct
rnai
variou
cellular
factor
includ
la
polypyrimidin
tractbind
protein
ptb
human
vampassoci
protein
kda
despit
posit
result
potenti
shortcom
cellular
target
approach
suggest
experi
gener
viral
replic
sever
crippl
target
viral
gene
downregul
cellular
gene
moreov
cellular
targetdirect
inhibit
appli
therapi
patient
safeti
must
thoroughli
demonstr
even
total
loss
target
gene
express
would
harm
likewis
approach
particular
could
benefit
develop
strategi
spatial
cell
tissu
viru
tropism
andor
tempor
upon
viral
infect
regul
rnai
induct
anoth
strategi
viral
evolut
might
thwart
simultan
applic
multipl
rnaiinduc
speci
target
sever
sequenc
combinatori
strategi
basi
haart
treatment
hiv
improv
patient
respons
antivir
drug
administ
cocktail
sever
compound
target
multipl
viral
fact
combin
rnai
might
improv
efficaci
singletarget
treatment
sever
mechan
first
shown
synergist
inhibit
viral
replic
achiev
target
multipl
loci
secondli
simultan
target
sever
viral
gene
thu
block
multipl
step
viral
life
cycl
enhanc
inhibit
also
similarli
simultan
target
multipl
cellular
cofactor
hiv
receptor
coreceptor
led
enhanc
viral
final
overcom
potent
inhibit
viru
would
accumul
multipl
mutat
significantli
reduc
possibl
fulli
resist
mutant
analog
combinatori
approach
combin
rnai
interfer
gene
therapymedi
inhibitor
viral
replic
exampl
rossi
et
achiev
enhanc
hiv
inhibit
use
gene
therapi
vector
simultan
express
sirna
direct
hiv
rev
protein
nucleolarloc
tar
decoy
rna
ribozym
downregul
express
cellular
coreceptor
fact
rnai
might
combin
effect
number
antivir
therapeut
includ
dominantneg
antivir
protein
tradit
chemotherapeut
drug
current
use
haart
futur
work
need
synthes
principl
identifi
antivir
strategi
provid
effect
longterm
suppress
viral
replic
pathogenesi
clear
abund
studi
recent
year
mani
possibl
strategi
option
exist
block
viral
replic
rnai
therefor
field
advanc
toward
clinic
trial
import
pose
key
question
one
design
optim
antivir
rnaibas
therapi
addit
extens
empir
data
avail
safeti
efficaci
viral
escap
consider
describ
would
use
draw
upon
grow
wealth
comput
bioinformat
approach
identifi
promis
start
point
empir
test
antivir
strategi
virus
often
contain
complex
gene
regul
circuit
exhibit
nonlinear
target
specif
loci
circuitri
may
optim
suppress
viral
replic
exampl
analysi
bacteriophag
model
system
endi
et
employ
comput
model
determin
antisensemedi
therapi
target
viral
gene
involv
negativefeedback
regul
order
maxim
resist
viral
escap
recent
report
use
agentbas
stochast
simul
describ
hiv
replic
evolut
presenc
rnai
direct
hiv
tar
element
model
use
identifi
criteria
sirna
dose
deliveri
effici
rnai
target
sequenc
choic
within
tar
requir
maxim
probabl
longterm
viral
prepar
clinic
antivir
rnai
therapi
would
also
prudent
draw
upon
experi
gain
use
haart
manag
hiv
infect
clinic
success
haart
improv
analyz
patient
primari
viral
isol
predict
viral
drug
suscept
therebi
design
drug
regimen
resist
treatment
direct
although
costli
approach
perform
batteri
vitro
assay
test
viral
isol
suscept
differ
therapi
howev
costeffect
approach
employ
statist
bioinformat
analysi
viral
genotyp
domin
viral
genet
sequenc
present
patient
part
approach
use
larg
data
set
correl
viral
genotyp
past
histori
success
failur
specif
drug
regimen
guid
choic
optim
drug
recent
develop
enhanc
predict
abil
bioinformat
method
explicitli
includ
consider
viral
evolut
exampl
beerenwinkel
et
develop
strategi
util
predict
phenotyp
viral
isol
closest
genet
neighbor
although
approach
proven
effect
mani
case
least
short
term
mani
patient
eventu
develop
drugresist
total
experi
suggest
comput
tool
combin
relev
vitro
experi
anim
model
improv
chanc
clinic
success
avoid
potenti
pitfal
antivir
rnai
therapi
prepar
human
trial
importantli
proactiv
measur
might
preclud
need
amass
larg
databas
clinic
trial
effect
solut
identifi
summari
sinc
first
demonstr
rnai
mammalian
cell
year
enorm
progress
toward
appli
rnai
antivir
therapi
furthermor
clinic
applic
benefit
advantag
rnaibas
antivir
therapi
hold
tradit
drug
sinc
rnai
mechan
make
use
innat
cellular
pathway
requir
introduct
dsrna
trigger
offer
potenti
effect
antivir
therapi
minim
side
effect
consider
especi
relev
compar
current
treatment
chronic
infect
hiv
consist
chemotherapeut
drug
requir
complic
dose
schedul
induc
sever
side
effect
undermin
patient
complianc
even
caus
novel
medic
moreov
although
antivir
rnai
therapi
need
target
sequenc
tailor
particular
viru
actual
therapeut
deliveri
method
larg
similar
across
mani
target
consequ
possibl
develop
new
rnaibas
therapi
rapidli
achiev
small
molecul
drug
readili
adapt
approach
would
use
target
virus
whose
domin
genotyp
phenotyp
vari
season
influenza
especi
case
vaccin
difficult
predict
year
vaccin
ineffect
target
domin
strain
similarli
effect
antivir
rnaibas
therapi
develop
might
serv
basi
quickli
develop
treatment
emerg
viral
infect
ebola
sarscov
treatment
could
made
avail
treat
acut
infect
even
full
biolog
novel
virus
elucid
final
rnaibas
therapi
might
provid
first
line
defens
viral
strain
acquir
natur
human
mean
resist
drug
vaccin
previous
found
effect
although
much
work
remain
carri
clinic
success
realiz
rnaibas
therapi
emerg
highli
promis
modular
versatil
prospect
treat
viral
infect
